



**November 06, 2014, Mumbai, India**

## **GlaxoSmithKline Pharmaceuticals announces Q3 Results**

---

GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the third quarter ended September 30, 2014.

The core Pharmaceuticals business grew by 20.4% for the quarter. Impact of the previous year National List of Essential Medicines (NLEM) price adjustments were felt in the corresponding quarter last year.

Net Profit before exceptional items grew by 31.3% for the quarter.

Dr. Hasit B. Joshipura, Managing Director, said, "The brands impacted by price adjustments have shown improved volume growth."

### **About GlaxoSmithKline:**

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com).

### **For enquiries, please contact:**

Nandini Goswami  
General Manager, Corporate Communications

+91 22 24959203  
[nandini.x.goswami@gsk.com](mailto:nandini.x.goswami@gsk.com)